US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ヨーロッパ
EU
Scemi (MLCMI) 銘柄情報

Scemi (MLCMI)

3.68

0.00

(0.00%)

終了 7月5日 12:30AM

Scemi (MLCMI) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

3.68

( - )

買値

2.84

売値

4.50

出来高

0.00

0.00 日の範囲 0.00

2.92 52 週間の範囲 3.86

時価総額

前日終値

3.68

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

750 €

発行済株式数

1,051,733

配当利回り

PER

36.58

1 株当たり利益 (EPS)

0.1

歳入

3.61M

純利益

105.82k

Societe de Conseil en Externalisation et en Marketing Internet - SCEMI Société Anonyme provides computer data entry and processing services. The company was incorporated in 2003 and is headquartered in Boulogne-Billancourt, France. Societe de Conseil en Externalisation et en Marketing Internet - SCEMI Société Anonyme provides computer data entry and processing services. The company was incorporated in 2003 and is headquartered in Boulogne-Billancourt, France.

セクター

Industrials

業界

Corporate Services

ウェブサイト

scemi.fr

本社

Boulogne-billancourt, France

設立

2026

Scemi is listed in the Industrials sector of the ユーロネクスト with ticker MLCMI. The last closing price for Scemi was 3.68 €. Over the last year, Scemi shares have traded in a share price range of 2.92 € to 3.86 €.

Scemi currently has 1,051,733 shares in issue. The market capitalisation of Scemi is 3.87 € million. Scemi has a price to earnings ratio (PE ratio) of 36.58.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	3.68	3.68	3.68	0	0	DE
4	0.38	11.5151515152	3.3	3.76	3.08	593	3.69303498	DE
12	0.12	3.37078651685	3.56	3.76	3.08	267	3.61278313	DE
26	0.46	14.2857142857	3.22	3.76	3.08	153	3.56341185	DE
52	-0.16	-4.16666666667	3.84	3.86	2.92	160	3.49248968	DE
156	-1.18	-24.2798353909	4.86	5	2.48	89	3.65820668	DE
260	0.66	21.8543046358	3.02	6.4	2.48	62	3.72143557	DE

MLCMI - Frequently Asked Questions (FAQ)

What is the current Scemi share price?

The current share price of Scemi is 3.68 €

How many Scemi shares are in issue?

Scemi has 1,051,733 shares in issue

What is the market cap of Scemi?

The market capitalisation of Scemi is EUR 3.87M

What is the 1 year trading range for Scemi share price?

Scemi has traded in the range of 2.92 € to 3.86 € during the past year

What is the PE ratio of Scemi?

The price to earnings ratio of Scemi is 36.58

What is the cash to sales ratio of Scemi?

The cash to sales ratio of Scemi is 1.07

What is the registered address of Scemi?

The registered address for Scemi is 9-13, avenue du Général Leclerc, Boulogne-Billancourt, Ile-de-France, 92100

What is the Scemi website address?

The website address for Scemi is scemi.fr

Which industry sector does Scemi operate in?

Scemi operates in the Corporate Services sector

gfp927z

gfp927z 16秒前

US Stablecoin consortium -

A huge development last week for the coming US national Stablecoin system. 140 of the biggest players in finance are forming a consortium to run and own the new US digital dollar / stablecoin system they call 'Open US' (links below). The stablecoin is lik

gfp927z

gfp927z 4分前

Bigworld, It looks like a huge development last week for the coming US national Stablecoin system. 140 of the biggest players in finance are forming a consortium to run and own the new US digital dollar / stablecoin system they call 'Open US' (links below). The stablecoin is like a CBDC (digital

Twiggs333

Twiggs333 25分前

GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech.

Jazz Pharmaceuticals acquired GW Pharmaceuticals for approximately $7.2 billion.

Why does that matter for psychedelic biotech?

Because G

Twiggs333

Twiggs333 25分前

GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech.

Jazz Pharmaceuticals acquired GW Pharmaceuticals for approximately $7.2 billion.

Why does that matter for psychedelic biotech?

Because G

Twiggs333

Twiggs333 25分前

GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech.

Jazz Pharmaceuticals acquired GW Pharmaceuticals for approximately $7.2 billion.

Why does that matter for psychedelic biotech?

Because G

Twiggs333

Twiggs333 25分前

GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech.

Jazz Pharmaceuticals acquired GW Pharmaceuticals for approximately $7.2 billion.

Why does that matter for psychedelic biotech?

Because G

OMOLIVES

OMOLIVES 30分前

Happy Fourth of July to all!...and a big thank you to the French. Vive la France!:

https://x.com/Phoenix2A_1980s/status/2073453266428387385

4u2nv2

4u2nv2 31分前

Every filing from the time Paul and Ben took over said there were 3 preferred shareholders. The third one was never named. Now, it's interesting to question how Newby got controlling interest when we do not know all of the facts concerning what Ben really wanted to accomplish with taking on the comm

Eli's Gone

Eli's Gone 43分前

I'm in: 11-5-24-19

Eli's Gone

Eli's Gone 44分前

gfp927z

gfp927z 44分前

>>> Look At Who Joined Open USD To Understand Where Money Is Going

Forbes

by Zennon Kapron

Jul 02, 2026

https://www.forbes.com/sites/digital-assets/2026/07/02/look-at-who-joined-open-usd-to-understand-where-money-is-going/

Sammy boy

Sammy boy 49分前

Said it 4 months ago Bessent is the problem ! There is a reason he cold-cocked Tommy Boy.

misterfishman

misterfishman 1時間前

Me too my side hobbies are researching new forms of energy from the enviroment,been at this for more than 20 yrs now and have accumilated a great deal oh knowledge.

Atlanta1

Atlanta1 1時間前

Joey - Why do you waste time on this lunatic?

FeMike

FeMike 1時間前

The original randomised primary endpoint (PFS) was negative and showed harm,

The simple fact that you don’t understand pseudo progression is more than enough to establish as also fact that you have no idea what you’re talking about.

1jas

1jas 1時間前

If you go to otcmarkets for AFFU news dated August 22 2023 it does mention AFFU and Dell partnership.

nyt

3 yrs down 79%. 5 yrs down 57%. 10 yrs down over 80%

gemstone57

gemstone57 1時間前

Happy Fourth of July guys we live in the greatest Nation on earth.

Tadaaa

Tadaaa 2時間前

johnydollar

johnydollar 2時間前

Have you ever wondered why clown fish like to hang out around the sea anemones........

😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆

GoodGuyBill

GoodGuyBill 2時間前

rcbindustry

rcbindustry 2時間前

I'm staying on the sidelines for now. Rocket Companies has potential over the long term, but I think the stock will continue to depend heavily on interest rates and the housing market. I'll be watching the next few quarters before becoming more optimistic.

Genz2

Genz2 2時間前

Now who would have thought of what Steven K Sprague came up with on X recently??? This country, Microsoft, Intel and Wave need Steven’s thinking!!!! If Steven’s court case is still in abeyance that is a real travesty!!! Steven is VERY UNIQUE in how he can masterfully come up with solutions that a

johnydollar

johnydollar 2時間前

You mean naked short enrichment right...........

😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 Ƕ

Roman516

Roman516 2時間前

Happy 4th of July to all, GoodGuyBill, yes, I agree with you and your comment that "$35 billion is far too low for a treatment that will treat all tumor-based cancers (and we are not even discussing DIRECT, the combo patent, etc)."

If in fact, DCVax-D is able to address the majority o

Sterling Infrastructure

PM Capital Global Opport...

Champion Iron (QX)

Sigma Fin.frn13

CFM Indosuez Wealth

FROF31 - 01/2031

Renault until 05/26

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。